Core Points - Company received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false financial reporting [1] - The investigation is related to the company's periodic reports and financial data [1] - If the investigation leads to a determination of significant violations, the company may face mandatory delisting due to serious misconduct [1]

Group 1 - The company *ST Changyao received a notice from the China Securities Regulatory Commission (CSRC) on November 7, 2025, regarding an investigation due to suspected false reporting of financial data [1] - The CSRC has decided to initiate a case against the company, which may lead to significant legal consequences [1] - If the investigation confirms major violations, the company’s stock may face mandatory delisting due to serious legal infractions [1]

Core Viewpoint - *ST Changyao has been notified by the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false reporting of financial data, which could lead to significant legal consequences including potential delisting of its stock [1] Group 1: Investigation Details - On November 7, 2025, *ST Changyao received a "Notice of Investigation" from the CSRC due to allegations of false records in periodic reports [1] - The CSRC's decision to initiate an investigation indicates serious concerns regarding the company's financial disclosures [1] Group 2: Potential Consequences - If the investigation confirms major violations, the company may face mandatory delisting from the stock market [1] - The company has stated its commitment to cooperate with the CSRC during the investigation and will adhere to regulatory disclosure requirements [1]

Core Viewpoint - The company *ST长药 (300391.SZ) has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false reporting of financial data, which may lead to severe penalties and potential delisting from the Shenzhen Stock Exchange if found guilty [1] Summary by Relevant Sections - **Investigation Details** - The company was notified on November 7, 2025, about the investigation due to allegations of false financial reporting [1] - The CSRC's decision to initiate the investigation is based on relevant laws and regulations [1] - **Potential Consequences** - If the CSRC confirms the allegations and determines that they constitute a major violation under the revised Shenzhen Stock Exchange listing rules (2025), the company may face mandatory delisting [1]

*ST长药表示，若后续经中国证监会行政处罚认定的事实，触及《深圳证券交易所创业板股票上市规则 (2025年修订)》规定的重大违法强制退市情形，公司股票将被实施重大违法强制退市。 北京商报讯（记者 丁宁）11月7日晚间，*ST长药（300391）发布公告称，公司于11月7日收到中国证监 会下发的《立案告知书》，因公司涉嫌定期报告等财务数据虚假记载，根据《中华人民共和国证券法》 《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 ...

Core Viewpoint - *ST Changyao (300391.SZ) has been notified by the China Securities Regulatory Commission (CSRC) regarding an investigation into alleged false reporting of financial data, which may lead to significant penalties and potential delisting from the Shenzhen Stock Exchange if found guilty [1] Summary by Relevant Sections - **Investigation Details** - The company received a "Notice of Investigation" from the CSRC on November 7, 2025, due to suspected false records in periodic financial reports [1] - **Potential Consequences** - If the CSRC confirms the violations, the company may face administrative penalties that could trigger mandatory delisting under the revised Shenzhen Stock Exchange listing rules for the Growth Enterprise Market (2025) [1]

Core Viewpoint - *ST Changyao (300391.SZ) has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false reporting of financial data, which may lead to significant penalties and potential delisting if found guilty [1] Summary by Relevant Sections - **Investigation Details** - The company is under investigation for allegedly falsifying financial data in periodic reports, as indicated by the CSRC's notice (Case No. 0042025020) [1] - **Legal Framework** - The investigation is based on violations of the Securities Law of the People's Republic of China and the Administrative Penalty Law, among other regulations [1] - **Potential Consequences** - If the CSRC confirms the violations, the company may face mandatory delisting under the Shenzhen Stock Exchange's rules for significant legal violations [1]

证券代码：300391 证券简称：*ST长药 公告编号：2025-097 长江医药控股股份有限公司 关于公司收到中国证券监督管理委员会立案告知书 暨风险提示的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司(以下简称"公司")于2025年11月7日收到中国 证券监督管理委员会(以下简称"中国证监会")下发的《立案告知书》(证监立 案字0042025020号),因公司涉嫌定期报告等财务数据虚假记载，根据《中华人民 共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对 公司立案。 若后续经中国证监会行政处罚认定的事实，触及《深圳证券交易所创业板股 票上市规则(2025年修订)》规定的重大违法强制退市情形，公司股票将被实施重 大违法强制退市。敬请投资者注意投资风险。 在立案调查期间，公司将积极配合中国证监会的调查工作，并严格按照监管 要求履行信息披露义务。公司指定的信息披露媒体为《证券时报》《证券日报》 《上海证券报》《中国证券报》以及巨潮资讯网(www.cninfo.com.cn)，有关公 司的信息均以上述指定媒体刊登 ...

证券代码：300391 证券简称：*ST长药 公告编号：2025-096 特别风险提示： 本次担保后，公司及控股子公司提供担保总余额为人民币129,913.71万元， 占公司最近一期经审计净资产的比例为-300.14%；公司及控股子公司对资产负债 率超过70%的单位担保金额为人民币75,484.93万元，占公司最近一期经审计净资 产的比例为-174.39%；公司及控股子公司对合并报表外单位提供的担保总余额 3,022.78万元，占公司最近一期经审计净资产的比例为-6.98%；请投资者充分关 注担保风险。 一、担保情况概述 长江医药控股股份有限公司（以下简称"公司"、"长药控股"）于2025年 4月17日召开第五届董事会第二十三次会议、于2025年5月13日召开的2024年年度 股东会，审议通过了《关于2025年度公司及子公司向银行申请综合授信额度暨预 计担保额度的议案》，公司拟在确保规范运作和风险可控的前提下为各级全资和 控股子公司提供合计不超过人民币225,000万元的担保额度。其中，对资产负债 率未超过70%的子公司提供的担保额度为不超过人民币30,000万元，对资产负债 率超过70%的子公司提供的担保额 ...

Company Summary - *ST Changyao announced a provision for asset impairment totaling approximately 144 million yuan for the period from January to September 2025, which will impact the total profit for the same period by about -144 million yuan, with credit impairment losses accounting for approximately -144 million yuan and asset impairment losses for about -250,000 yuan [1] - For the first half of 2025, the revenue composition of *ST Changyao is as follows: 68.0% from the photovoltaic industry and 32.0% from the pharmaceutical industry [1] - As of the report date, *ST Changyao has a market capitalization of 1.3 billion yuan [1] Industry Summary - The announcement of significant asset impairment provisions indicates potential challenges within the company, particularly in the photovoltaic and pharmaceutical sectors, which may affect investor sentiment and market performance [1]